肿瘤坏死因子受体相关因子6的表达对食管鳞状细胞癌预后的影响

Effect of TRAF6 expression on the prognosis of esophageal squamous cell carcinoma

目的探讨肿瘤坏死因子受体相关因子6(TRAF6)在食管鳞状细胞癌(ESCC)组织中的表达与复发和生存的关系。方法选取2012年12月至2014年2月在云南省第三人民医院接受根治性切除术治疗的经病理证实为ESCC的病人478例作为研究对象。采用免疫组织化学法检测ESCC病人癌组织中TRAF6的表达。并探讨TRAF6的表达与ESCC病人复发和生存的相关性。结果478例ESCC病人中,341例(71.3%)符合TRAF6表达阳性标准。TRAF6表达与性别、年龄、肿瘤大小无关(P>0.05),但是与ESCC病人的TNM分期、淋巴结转移、复发和死亡状况显著相关(P<0.05)。淋巴结转移、较高临床分期、发生复发或死亡的病人TRAF6阳性表达率高。进一步分析发现,TRAF6阳性表达的ESCC病人复发和死亡风险增加[HR(95%CI):2.47(1.63~3.84),3.05(2.37~3.48)]。结论TRAF6在ESCC癌组织中的表达参与ESCC的发生发展,TRAF6表达阳性病人复发和死亡的风险增加;TRAF6可作为ESCC潜在的治疗靶点。

Objective To investigate the relationship between tumor necrosis factor receptor associated factor 6(TRAF6)expression and the recurrence and survival in patients with esophageal squamous cell carcinoma(ESCC).Methods A total of 478 patients pathologically confirmed with ESCC who underwent radical resection in The Third People’s Hospital of Yunnan Province from December 2012 to February 2014 were included as the research subjects.The expression of TRAF6 in cancer tissues of ESCC patients was evaluated by immunohistochemistry.The relationship between the expression of TRAF6 and the recurrence and survival of ESCC patients were investigated.Results Among the 478 ESCC patients,341(71.3%)met the TRAF6 positive expression criteria.TRAF6 expression was not associated with gender,age,and tumor size(P>0.05),but was significantly associated with TNM stage,lymph node metastasis,recurrence,and death status in ESCC patients(P<0.05).Patients with lymph node metastasis,higher clinical stage,and recurrence or death,have a high rate of TRAF6 positive expression.Further analysis suggested an increased risk of recurrence and death in ESCC patients showing positive TRAF6 expression[HR(95%CI):2.47(1.63-3.84),3.05(2.37-3.48)].Conclusions The expression of TRAF6 in ESCC cancer tissues is involved in the development of ESCC.The risk of recurrence and death is increased in patients with positive TRAF6 expression.TRAF6 can be used as a potential therapeutic target for ESCC.